Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials,

For Part 1 of the Phase III CheckMate -227 clinical trial, the company announced three-year follow-up data showing that Opdivo (nivolumab) plus Yervoy …, For Part 1 of the Phase III CheckMate -227 clinical trial, the company announced three-year follow-up data showing that Opdivo (nivolumab) plus Yervoy …, Read More

Scroll to Top